Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 4/20 | 0.52 |
| ▸ | CFTR | P13569 | 12/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31579186 | 0.85 | TUBB4A (0.49) | FYNEGLN2AAK1 | |
| SCHEMBL9378017 | 0.80 | PDE4D (0.54) | CFTR | |
| SCHEMBL24370656 | 0.79 | CFTR (0.57) | CFTRMAPT | |
| SCHEMBL29599257 | 0.79 | CFTR (0.57) | CFTRMAPT | |
| SCHEMBL26601208 | 0.79 | CFTR (0.49) | FYNCFTRMAPT | |
| SCHEMBL30315211 | 0.77 | CFTR (0.58) | CFTR | |
| SCHEMBL21575262 | 0.77 | AAK1 (0.49) | CFTRMAPTEGLN2AAK1 | |
| SCHEMBL27244533 | 0.77 | CFTR (0.58) | CFTR | |
| SCHEMBL28058890 | 0.76 | GRM7 (0.56) | FYNPIK3CGMAPT | |
| SCHEMBL7366534 | 0.76 | PDE4D (0.40) | CFTRAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023204629-A1 | METHOD FOR PRODUCING CFTR ACTIVATOR COMPOUND AND INTERMEDIATE USED THEREFOR | 일동제약(주) | 2023-10-26 | — | — | WO | claimed |
| CN-114380835-B | Preparation method of 7- (3,4-dimethoxyphenyl) -2-pyrazole [1,5-A ] pyrimidine carboxylic acid | 南京桦冠生物技术有限公司 | 2022-12-27 | — | — | CN | claimed |
| US-20240199623-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| WO-2024096629-A1 | EYE DROP COMPOSITION COMPRISING CFTR MODULATOR COMPOUND | 일동제약 주식회사 | 2024-05-10 | — | — | WO | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230080486-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | S2CBIO INC. (KR) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | FYN 3317/4885CFTR 4/4885PIK3CG 129/4885 |
| US-20230080486-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CFTR, PDE4A, PDE6C | FYN 4324/4885CFTR 1/4885PIK3CG 164/4885 |
| US-20240199623-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | PDE4A, PDE4B, PDE6C | FYN 3242/4885CFTR 4/4885PIK3CG 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.